ERBB2 and gastric cancer: Besides traditional small-molecule targeted drugs and antibody drugs, drugs based on new mechanisms of action, such as bispecific antibodies, improved ADCs and antibody neodegrader conjugate (AnDC), are expected to exhibit unique advantages in the treatment of HER2-positive GC.